Point of care susceptibility testing in primary care:does it lead to a more appropriate prescription of antibiotics in patients with uncomplicated urinary tract infections? Protocol for a randomized controlled trial by Holm, Anne et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Point of care susceptibility testing in primary care
Holm, Anne; Cordoba Currea, Gloria Cristina; Sørensen, Tina Møller; Jessen, Lisbeth Rem;
Siersma, Volkert Dirk; Bjerrum, Lars
Published in:
B M C Family Practice
DOI:
10.1186/s12875-015-0322-x
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Holm, A., Cordoba Currea, G. C., Sørensen, T. M., Jessen, L. R., Siersma, V. D., & Bjerrum, L. (2015). Point of
care susceptibility testing in primary care: does it lead to a more appropriate prescription of antibiotics in patients
with uncomplicated urinary tract infections? Protocol for a randomized controlled trial. B M C Family Practice, 16,
[106]. https://doi.org/10.1186/s12875-015-0322-x
Download date: 03. Feb. 2020
STUDY PROTOCOL Open Access
Point of care susceptibility testing in primary
care - does it lead to a more appropriate
prescription of antibiotics in patients with
uncomplicated urinary tract infections?
Protocol for a randomized controlled trial
Anne Holm1*, Gloria Cordoba1, Tina Møller Sørensen2, Lisbeth Rem Jessen2, Volkert Siersma1 and Lars Bjerrum1
Abstract
Background: Urinary tract infection (UTI) is a common infection in primary care and is the second leading reason
for prescription of antibiotics in Denmark. The diagnosis is often based on symptoms and urine dip-stick, which has
limited validity, causing the risk of unnecessary antibiotic prescription. Additionally, with increasing antibiotic resistance,
the risk of choosing an antibiotic to which an infecting pathogen is resistant is rising. Combined point-of-care-tests
(POCT) for urine culture and susceptibility testing have been developed and validated for primary care, and performing
such a test in all patients with suspected UTI in primary care seems rational in order to reduce the use of inappropriate
antibiotics. However, the clinical effect of the culture and susceptibility test has not yet been investigated. This study
aims to investigate whether POCT urine culture and susceptibility testing decreases the inappropriate use of antibiotics
and leads to faster patient recovery.
Methods/design: Randomized controlled open label trial of two diagnostic approaches. 750 patients with symptoms
of uncomplicated UTI, consecutively contacting their general practitioner (GP), randomized to either POCT urine culture
and susceptibility testing and targeted treatment or POCT urine culture without susceptibility testing and empirical
treatment. Treatment is started when the POCT is read. The two groups are compared with regard to appropriate
choice of antibiotics, clinical remission, and microbiological cure rates.
Discussion: The results of this study may provide important evidence to recommend POCT culture and
susceptibility testing in all patients with suspected uncomplicated UTI. This could become an additional
strategy to fight antibiotic resistance.
Trial registration: ClinicalTrials.gov NCT02323087.
Background
Antibiotic resistance is rapidly spreading, making it one
of the most serious threats to human health. The World
Health Organization has stated that a post-antibiotic
era is a very real possibility and that urgent actions are
needed in order to maintain the effect of antibiotics [1].
Primary health care in Denmark is responsible for
about 90 % of all redeemed prescriptions of antibiotics,
and it is known that a high out-patient consumption of
antibiotics leads to high levels of resistance [2, 3]. Thus,
a cornerstone in the efforts to reduce antibiotic resist-
ance is to reduce and improve prescription of antibiotics
in primary health care.
In 2008, 1.8 % of all patients consulting their GP in
Denmark were diagnosed with a UTI [4]. Resistant strains
of E. Coli, which is the causative organism in 70–80 % of
all UTIs, are spreading world-wide [5, 6]. In Denmark,
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33–40 % of E. Coli isolated from urine samples from pri-
mary care are resistant to sulfamethizole and 6–10 % to
pivmecillinam, which account for about 80 % of all anti-
biotic treatments of adults with UTI in primary care in
Denmark [3, 7]. It is, therefore, critical that a UTI is treated
only when clinically indicated and using an appropriate
antibiotic, i.e., one to which the infecting pathogen is sus-
ceptible, taking into account the use of first-line agents
over second-line agents.
Urine culture is necessary to accurately determine if a
patient has a UTI since other tests have limited predict-
ive values in primary care and treating based on symp-
toms can cause up to 50 % being inappropriately treated
[8, 9]. Susceptibility testing adds the advantage to predict
whether a first-line antibiotic can be expected to elimin-
ate the infecting pathogen. However, delaying treatment
for several days while waiting for the results of the sus-
ceptibility test cannot be justified as symptoms are pain-
ful and affect quality of life [10, 11]. Point of care test
(POCT) culture and susceptibility testing provides the
result within 24 h, and can, therefore, be used to target
individual therapy without compromising patient welfare.
Inappropriate antibiotic prescribing can be partly avoided
by performing a POCT culture since this will assumedly
eliminate treatment of patients without bacteriuria. How-
ever taking into account the above-mentioned resistance
rates in E. Coli and for example enterococci being inher-
ently resistant to both antibiotics, this could result in
about 20–30 % inappropriate antibiotic prescriptions for
UTI. Adding susceptibility testing to the POCT should
raise the appropriate antibiotic prescriptions above 90 %.
This study aims to answer the questions: 1) Does POCT
urine culture and susceptibility testing decrease the use of
inappropriate antibiotics, and 2) Does targeted therapy
improve clinical outcomes in patients with suspected
uncomplicated UTI in general practice when compared
to POCT urine culture without susceptibility testing? We
hypothesize that the use of POCT susceptibility testing
improves the following outcomes: Appropriate choice of
antibiotic, clinical remission, and microbiological cure
rate.
Methods
Study design
Randomized controlled open label trial of two diagnostic
approaches in a primary care setting.
Recruitment process
General practitioners (GPs) 200 general practices in the
Copenhagen area will be contacted by letter with the
aim of recruiting 50 GPs. All GPs will receive relevant
training in the use of POCT culture and susceptibility
testing, and their skills will be validated using an online
test on how to read the POCT.
Patients
Patients presenting with symptoms of UTI will be re-
cruited at the general practice during consultation. To
ensure interpretation of POCT within 24 h, only patients
contacting practice from Monday to Thursday will be in-
cluded. Each GP will recruit and randomize 15 patients.
Inclusion criteria
Female adult patients, 18 years or older, presenting at their
GP with dysuria, frequency or urgency, which has been
present for 7 days or less, and for which the GP suspects
uncomplicated UTI (including recurrent UTI, uncompli-
cated diabetes mellitus defined as orally treated, well regu-
lated and without secondary complications, and elderly
patients). Patients should be able to deliver a mid-stream
urine sample, to provide informed consent, and should be
willing and able to fill out a symptom diary.
Exclusion criteria
 Negative dip-stick analysis on leucocytes and nitrites
(to reduce the number of negative cultures)
 Complicated UTI
– Known pregnancy
– Severe systemic symptoms, high fever, flank pain
– Recent bladder surgery (within past 4 weeks)
– Urinary tract abnormalities
 Serious systemic disease
– Life-threatening cancer
– Insulin-dependent diabetes
– Long-term corticosteroid treatment
– Other conditions with compromised immunity
 Former participation in the study
 Patients presenting on a Friday (since POCT is read
after 24 h)
Randomization and groups
The patients are block randomized in blocks of 10 to
ensure approximately equal sizing of the groups. The
randomization group for each patient is placed in a
sealed envelope which is opened either during or after
consultation.
 For the intervention group, POCT culture and
susceptibility testing is performed. Treatment is
based on the result of the susceptibility test and
clinical guidelines.
 For the control group, POCT culture without
susceptibility testing is performed, and treatment is
based on clinical guidelines.
Informed consent
All patients receive oral and written information before
signing informed consent forms.
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Screening logs
All participating general practitioners, secretaries, and
nurses will be asked to maintain an anonymous screen-
ing log of all patients fulfilling the inclusion criteria in
the inclusion period. This will be used to assess selection
and its effect on the study results and for the attrition
flow chart.
Data collection
Case-report form
After oral and written information about the project and
written consent to enrollment, the GP will take a struc-
tured history and fill out a case report form. Data from
day 1 consist of:
 Name and social-security number
 Drug allergies
 Diabetes
 Number of UTIs within past year
 Symptoms of UTI
– Dysuria
– Frequency
– Urgency
 Duration of symptoms
 Randomization group
The patients are asked to contact the GP the next morn-
ing by telephone or e-mail for treatment. The patients are
also asked to contact the GP if symptoms persist after 4–5
days. The GP can advise on painkillers if necessary.
The next day, the GP will read the plate and inform
the patient about the result and potential treatment with
antibiotics. The GP will complete the case report form
including the following data:
 Reading of culture plate
– No significant growth of uro-pathogens
– Significant growth of at least one uro-pathogen
– Inconclusive
 For identified uro-pathogen(s):
– Species
– Amount in cfu/mL
– Resistance pattern towards trimetroprim,
sulfamethizol, ampicillin, nitrofurantoin, and
pivmecillinam (intervention group)
 Treatment:
– Name, dose, and duration of antibiotic
Symptom diary
The patients are asked to compile and return a paper
symptom diary. Through personalized text messages,
they are reminded on day 3 to fill out the diary and on
day 7 to send it to the Section of General Practice, Uni-
versity of Copenhagen. If they have not sent the diary
on day 10 or do not have a cell phone, they receive a
phone call. The diary has been face- and content validated
through focus groups and personal interviews. The scales
for symptom severity, bothersomeness and impact on
daily activities are currently under psychometrical valid-
ation using the partial credit Rasch model for polytomous
items. The secondary outcome of clinical cure is measured
using a single item where the patient by the end of each
day answers if her symptoms of urinary tract infection are
completely gone. The scales for symptom burden are not
a part of the secondary outcome but serves to improve
the patient’s evaluation of her own cure.
The diary measures:
 Employment status, job and number of employees
 Use of medication other than antibiotics and
painkillers
 Symptom severity on day 1–7
 Symptom bothersomeness on day 1
 Impact on daily activities on day 1
 Use and possible change of antibiotics on day 1–7
 Use of painkillers on day 1–7
 Re-consultation with their GP/out-of-hour service
on day 1–7
 Sick-leave on day 1–7
 Day of becoming symptom-free
Urine samples
A mid-stream urine sample from the day of consultation
will be divided in two. One part is sent to the local
microbiological department, and the other part will be
examined at the general practice using the POCT. On
day 14 another urine sample will be sent to the local
microbiological laboratory for culture.
Microbiological analyses performed at the microbiological
laboratory– Gold standard
A mid-stream urine sample from day 0 to day 14 are ana-
lyzed at the local microbiological laboratory. The sample
from day 0 serves as a quality control of the culture and
susceptibility testing performed in general practice. The
sample from day 14 is the microbiological outcome meas-
ure. The samples are transported to the microbiological
laboratory in Urine-Monovette® (Sarstedt) containing
boric acid to stabilize the bacterial count.
At the microbiological laboratory urine sample are
dispersed on Inoqul A™ Bi-plate (CHROMagar and blood
agar) with 10 μL on each half of the agar. The susceptibility
pattern is determined on Mueller Hinton agars with disks
containing mecillinam, cefpodoxim, cefuroxim, gentamicin,
piperacillin + tazobactam, meropenem, ampicillin, nalidixic
acid, trimethoprim, nitrofurantoin, sulfamethizol, and
vancomycin. All samples are quantified. If the bacterial
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count on the two agars on Inoqul A™ differs with more
than a factor 10, the procedure is repeated.
Significant growth is defined as growth of ≥103 colony
forming units per millilitre (cfu/mL) for E. coli and S.
saprofyticus, ≥104 cfu/mL for other typical uro-pathogens
and ≥105 cfu/ml for possible uro-pathogens following
current consensus [12]. All pathogens with significant
growth are identified and susceptibility pattern deter-
mined. Any pathogen growing at least 103 cfu/ml, unless
the above mentioned criteria are fulfilled, is classified as
contamination, and in these cases the susceptibility
pattern is not determined. Insignificant growth is de-
fined as ≤ 102 cfu/mL or less. Susceptibility pattern is
determined according to EUCAST and NordicAST rec-
ommendations. The internal quality control is performed
measuring inhibition zones on chosen reference strains
from American Type Culture Collection (ATCC) and
National Collection of Type Cultures (NCTC).
Microbiological analyses performed on-site at the general
practice
Culture (control group) Point-of-care culture will be
performed using ID Flexicult™ (SSI DIagnostica, Denmark)
which is a chromogenic agar plate for identification and
quantitation of urinary tract pathogens. The sample is
seeded with a 10 μL inoculation needle, the lid is
applied, and the agar plate incubated upside down at
35 °C overnight. The plate is read the next day. If it
is positive, no further incubation is needed, if it is
negative, incubation is continued until 24 h after in-
oculation. The bacterial identification is based on col-
ony color and size. The agar plate can be seen on the
right side of Fig. 2.
Culture and susceptibility testing (intervention
group) Urine culture and susceptibility testing will be
performed on the intervention group by means of a
POCT, the FLEXICULT™ SSI-Urinary Kit (SSI Diagnos-
tica, Denmark). The kit is a chromogen agar in an ordin-
ary Petri dish, but with higher sides. The Petri dish is
divided into 6 compartments: 1 large compartment for
quantitative analysis and 5 smaller compartments for sus-
ceptibility testing. The agar in each of the smaller com-
partments contains 1 of 5 antimicrobials: trimethoprim,
sulfamethoxazole, ampicillin, nitrofurantoin, and mecilli-
nam. The agar plate can be seen on the left side of Fig. 2.
The agar plate is flooded with the urine specimen for a
couple of seconds and then incubated at 35 °C over
night. The plate is read on the following day.
As the concentrations of the antimicrobials in the 5
smaller compartments are adjusted in accordance with
breakpoints, growth on these compartments indicates
resistance of the pathogen in question and hence a poten-
tial risk of treatment failure.
Figure 1 illustrates the data collection process and
Fig. 2 explains the study design and the difference be-
tween the intervention and control arm.
Definition of outcomes
Primary outcome
– The proportion of patients receiving appropriate
antibiotic treatment on the day after consultation.
Data obtained from case-report form.
Day 1 
First consultation with symptoms of UTI
Case report 
form, day 1, 
the GP
Urine sample 
on POCT
Urine sample to 
the microbiolo-
gical laboratory
(gold standard)
Day 2
The POCT is read and treatment started
Case report 
form, day 2, 
filled out by 
filled out by 
Symptom diary finished 
the GP
Urine sample 
on POCT read
Day 7
Patient returns 
symptom diary
Patient starts 
antibiotic treat-
ment if POCT 
positive
Day 14
Control urine sample
Control urine 
sample to the 
microbiological 
laboratory
Fig. 1 Flow-chart for data collection. POCT: Point of care test. This
refers both to POCT culture and POCT culture and susceptibility
testing. GP: General practitioner
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Appropriate antibiotic treatment is defined as receiving
a first-line antibiotic to which the infecting organism is
susceptible, if there is significant growth in the gold stand-
ard or receiving any antibiotic to which the infecting
organism is susceptible if there is significant growth in the
gold standard if the patient is allergic or the infecting or-
ganism is resistant to all first-line antibiotics or not receiv-
ing an antibiotic if there is no significant growth in the
gold standard. The definition is illustrated in Fig. 3.
Secondary outcomes
– The proportion of patients who are asymptomatic
on the fourth day of treatment (clinical cure)
defined as the patient stating, her symptoms are
completely gone regardless of symptom score. Data
obtained from symptom diaries
– The proportion of patients with no significant
bacteriuria on day 14 (bacteriological cure). Data
obtained from control urine sample
Ethical aspects and patient safety
The study has been approved by the Ethical Committees
for the Capital Region of Denmark and reported to the
Danish Data Protection Agency. All patients entering this
study receive a higher level of diagnostics and treatment
than standard care at the moment. The improved diagnos-
tics and, thereby, the reduction of overtreatment will
benefit the individual patient more than the disadvantage
of delaying treatment. All data are kept under the same
security as other sensitive data at a GP office. In case of
any adverse event that could be attributed to participation
in the trial (eg. worsening of symptoms due to delay of
treatment), the GP in charge of care of the participant will
follow a flow-chart to determine if the trial-responsible
investigator should be notified and how fast. If the event is
considered harmless or unlikely to be related to the trial, it
is registered on the case-report form. If it is considered ser-
ious and likely related to the trial, the trial coordinator is
contacted by telephone within 24 h. At least two members
of the trial team evaluate serious events related to the trial
and decide if the trial team should be gathered. All adverse
events that could be attributed to participation in the trial
are recorded and analyzed biannually by the coordination
team. All results, positive, negative, and inconclusive, will
be published.
Analysis
Sample size calculation
Primary outcome The proportion of appropriately treated
patients in the control group is assumed to be 70–80 %
Fig. 2 Study design of randomized controlled trial. The figure shows the study design with the intervention arm on the left and the control arm
on the right. The shown agars are the ones used in the trial, courtesy of SSI Diagnostica
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based on an assumption that POCT culture will be precise
in determining UTI, but current local resistance rates
in E. Coli (70–80 % of infections) of about 6–10 % to
pivmecillinam (50 % of patients with UTI) and 30–40 %
to sulfamethizole (30 % of patients with UTI) will result
in inappropriate treatments as defined in Fig. 3 [3, 7].
To detect a statistically significant (α = 0.05) 10 percentage-
point difference between the two groups with 80 %
probability, assuming an intra-class correlation of 0.2
between patients in the same practice, a sample of 600
patients is needed. In order to take possible drop-outs
and sub-analyses into account, the study aims to enroll
750 patients.
Secondary outcomes
Clinical remission
McNulty and Ferry reported clinical cure rates of 69 %
on day 5 after targeted treatment with trimethoprim and
44 % on day 5 empiric treatment with pivmecillinam re-
spectively in patients with uncomplicated UTI [13, 14].
Assuming a cure rate of 60–70 % on the fourth day of
treatment (day 5) in the intervention group, a difference
of at least 15 percentage points could be detected with
the chosen sample while accounting for a 25 % drop-out
on clinical follow-up.
Bacteriological cure rate
Since bacteriological cure with empiric antibiotics on
day 8–10 is about 90 % [14] as reported in a Swedish
study, we are not expecting to see a significant difference
between the groups regarding this outcome.
Statistical analysis
Comparison of the two randomization groups for both
the primary and the secondary outcomes will be done
by means of an odds ratio (OR) from a logistic regres-
sion model; clustering within practices is adjusted for
by generalized estimating equations (GEE). Analyses
will be performed intention-to-treat, i.e., the patients
are analyzed in the groups they are randomized to re-
gardless of the treatment they actually received. Effect
modification – whether the effect of the intervention dif-
fers between subgroups in the data – will be investigated
for GP factors (organization of practice, performance in
reading the POCT), patient factors (age, concurrent ill-
ness, socio-demographic data, initial symptom score) and
microbiological factors (amount and species). If a suffi-
cient sample is obtained, sub-group analysis will be per-
formed for patients with diabetes, elderly patients and
patients with recurrent UTI since these groups are ex-
pected to benefit the most from the intervention. In an
additional analysis of the primary outcome, the group in-
appropriately treated will be divided into under-treated
and over-treated and analyzed in multinomial logistic re-
gression models. Comparison of cure-rates will be done
with Kaplan-Meier curves and log-rank tests. A P-value of
0.05 will be considered significant. Analyses will be per-
formed with SAS v9.4.
Discussion
In Denmark, POCT combined culture and susceptibility
testing has been in use for decades, and the use has in-
creased since introduction of the FLEXICULT™ SSI-
Urinary Kit. Despite this popularity no clinical trials
have yet validated its impact in clinical practice. This
study will investigate the effect of POCT susceptibility
testing on appropriate choice of antibiotics and on clin-
ical and microbiological cure in patients with uncom-
plicated UTI in primary care in Denmark.
The clinical effect and cost-effectiveness of POCT cul-
ture and susceptibility testing in UTI is currently being in-
vestigated by another research group [15]. Although both
studies aim at investigating the effect of the Flexicult on
the appropriateness of antibiotic use and the impact on
patient outcomes, there are at least three important differ-
ences. Firstly, in the study by Bates et al., the effect of
combined culture and susceptibility testing is compared to
Appropriate choice of treatment
Inappropriate 
choice of treat-
ment
Growth of uropathogen in gold standard (UTI)
Antibiotic 
prescribed?
Antibiotic 
prescribed?
Uropathogen 
sensitive to 
antibiotic?
Antibiotic Patient allergic or uro-
pathogen resistant to 
first-line antibiotics? 
Yes
YesNo
No
Yes
Yes
No
Yes NoYes
No
No
first-line? 
Fig. 3 Short title of figure: Flow-chart for primary outcome and
definition of appropriate and inappropriate choice of treatment
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various forms of standard care in a four-country multi-
center setting. The focus of the present study is nar-
rower, specifically aiming at determining the value of
the susceptibility component compared to culture alone
in a single region in Denmark. Secondly, all GPs in this
study are experienced users of POCT susceptibility test-
ing, and their skills are validated before enrollment of
patients as described under the recruitment process,
thus inter-practice variation is minimized. Thirdly, in
this study, both groups will have treatment delayed
until a positive culture is obtained, thereby minimizing
the number of culture-negative patients receiving in-
appropriate antibiotic treatment.
We have chosen to include patients with diabetes, re-
current UTI and elderly patients when they are other-
wise healthy and can be safely included. In the analysis,
they are investigated for effect modification and, if the
sample allows it, they are analyzed separately, since they
could be expected to benefit more from the intervention
than other groups.
A challenge of this study is the similarity between
the intervention and control groups. The potential
difference between the groups in this study will
mainly be driven by those patients in the control
group receiving an antibiotic to which, the infecting
pathogen is resistant. Since in vitro resistance rates in
Denmark against the most commonly used antibiotics
for UTI are 15–40 %, the effect could turn out minor
at present [3]. If the study detects no additional bene-
fit of susceptibility testing over culture alone, this will
provide important information for the Danish national
health care system. However, the results may not be
directly applicable to countries outside Scandinavia.
On the other hand, if susceptibility testing proves superior
to culture alone, the impact of such a finding will likely be
much higher in countries where resistance rates are
higher. In conclusion, the present study will test the hy-
pothesis that POCT susceptibility testing for uncompli-
cated UTI and individually targeted therapy will decrease
the use of inappropriate antibiotics and positively influ-
ence clinical cure rates. If this proves true, the results of
the study may provide important evidence to recommend
POCT susceptibility testing for patients with suspected
UTI. This could become one of many strategies to fight
antibiotic resistance.
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